Skip to Contents

Hanmi Pharmaceutical

We only Offer Accurate and Transparent Management Information.

We offer accurate and transparent management information.

(1 million won, K-IFRS)

Balance Sheet Table
Category	2023	2022	2021
Current assets	730,624	694,158	703,962
Non-current assets	1,168,045	1,230,428	1,232,767
Total Assets	1,898,668	1,924,586	1,936,729
Current liabilities	704,763	676,748	648,938
Non-current liabilities	93,695	238,611	359,531
Total Liabilities	798,458	915,359	1,008,469
Issued capital	31,405	30,765	30,196
Other equity	371,918	375,599	380,033
Retained earnings	581,979	452,298	396,916
Elements of other stockholder’s equity	(29,860)	13,174	(4,230)
Non-controlling interests	144,768	137,361	125,346
Total Equity	1,100,221	1,009,227	928,259
Total Equity and Liabilities	1,898,668	1,924,586	1,936,729

(1 million won, K-IFRS)

Income Statement Table
Category	2023	2022	2021
Sales revenue	1,490,887	1,331,547	1,203,186
Cost of sales	661,638	612,994	570,433
Gross profit	829,249	718,553	632,752
Selling general administrative expenses	426,789	406,146	361,309
Ordinary development costs	181,769	154,317	146,027
Operating income (Loss)	220,691	158,090	125,416
Finance income	7,247	7,964	9,229
Finance cost	29,486	23,494	18,763
Other income	25,403	14,127	10,727
Other expenses	28,588	27,138	22,912
Profit (Loss) before tax	193,967	121,013	103,697
Income tax expense	28,601	19,454	22,218
Profit (Loss)	165,366	101,558	81,478
Other comprehensive income	(54,713)	(6,757)	25,647
Total comprehensive income	110,652	94,801	107,125

Credit Ratings Table
Agency	2023	2022	2021
Korea Investors Service	A	A	A
NICE Investors Service	A	A	A

*Bond credit ratings are assigned when a bond is issued and the company is regularly assessed on a yearly basis